At SkylineDx, we’re on a mission to transform healthcare by offering scientifically robust and clinically relevant molecular diagnostic tests that address a current unmet medical need.
Whether it regards diagnosing faster, deselecting patients for procedures or finding therapy responders, our tests support care providers and patients in their treatment decision-making. Each test delves into the biology of the disease and analyses a patients’ unique gene expression, unraveling their individual disease profile and empowering those involved to make informed choices at pivotal moments in their lives.
We LIVE to make a difference
Our innovative medical technology is already making a significant impact. Our team is driven by scientific research, data science and clinical relevance. It is not a solo journey. While we are disease agnostic, we pride ourselves in having a very clear focus: bridging the gap between (academically) discovered biomarkers and commercially available diagnostic assays. This means we collaborate with esteemed medical (academic) centers in the United States and Europe to further develop their foundational and instrumental work in biomarker discovery. Once launched commercially, we sign commercial partnerships to strengthen the sales and marketing efforts, expanding the test’s footprint globally.
Value-based healthcare starts with comprehensive molecular diagnostics that address a clinical unmet need. In collaboration with our partners, we are dedicated to make these tests available in the real world setting through a focus on reimbursement and market access for patients.
STRIX is the best-known genus of the Owl-family and stands for proverbial wisdom and perception. While leading a somewhat hidden nocturnal existence, this bird keeps the ecosystem well-balanced. With his sharp attention to details and incredible line of sight, STRIX Services is uniquely equipped to make visible what otherwise remains hidden.Â
Under the wings of STRIX Services, a series of specific projects have been initiated aimed at biomarker discovery, with novel peer-reviewed and in-house developed biomarker tools. This service is now open for additional projects. Independent from the type of data, if you want to identify a sub-population through biomarkers, we will find it.
Melanoma is an aggressive type of skin cancer. In melanoma, we have an extensive collaboration named the Falcon R&D Program. As the falcon bird is known as an intelligent creature with unprecedented senses and skills, our R&D program is uniquely equipped to unveil new, detailed insights in the genomic, biologic and clinical nature of melanoma.Â
Under the wings of the Falcon R&D Program, a series of specific studies and projects has been initiated, aimed at developing and introducing an array of diagnostic utilities, to provide physicians with the tools to optimize the clinical pathway of their patients. Not by coincidence, related series of studies are named after birds of prey in the Falcon family.
The Panthera Program focuses on hematological malignancies, cancers that develop in blood cells. Tackling hematological cancer requires strength and intelligence. Conditions such as multiple myeloma hide deep in the bone marrow.
Infectious and Inflammatory diseases consist of many disorders and studies suggest that a dysfunction of the immune system seems to be an important shared characteristic. The first disease in this program is Kawasaki disease.
At the core, our greatest asset is our people. From visionary leaders to talented scientists and dedicated staff. Each member of the SkylineDx team is united by a shared commitment to make a difference. Our teams are structured to advance the research and development in 3 dedicated programs, personified by animal genera: Falcon R&D Program for Dermato-Oncology, Panthera R&D Program for hematology and Delphia R&D Program for infectious & inflammatory diseases.
What others have to say about us